Efficacy and Safety of Long-Acting β-Agonist/Long-Acting Muscarinic Antagonist Combinations Compare to Long-Acting β-Agonist/Inhaled Corticosteroid Combinations: A Network Meta-Analysis

被引：0
|
作者：
Ahmed, T. Said [1 ]
Al-Sarie, M. [2 ]
Srour, K. [2 ]
Rygielski, S. [3 ]
Ye, F. [2 ]
Hernandez, D. [4 ]
机构：
[1] Univ Toledo, Crit Care Pulm, 2801 W Bancroft St, Toledo, OH 43606 USA
[2] Univ Toledo, Internal Med, 2801 W Bancroft St, Toledo, OH 43606 USA
[3] Univ Toledo, Anesthesia, 2801 W Bancroft St, Toledo, OH 43606 USA
[4] Univ Toledo, Med Ctr, Pulm Crit Care Sleep Med, 2801 W Bancroft St, Toledo, OH 43606 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 197卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3045
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting (32-Agonist Plus Inhaled Long-Acting Muscarinic Antagonist vs Inhaled Long-Acting (32-Agonist Plus Inhaled Corticosteroid Fixed-Dose Combinations in COPD A Propensity Score-Inverse Probability of Treatment Weighting Cohort Study
    Wang, Meng-Ting
    Lai, Jyun-Heng
    Huang, Ya-Ling
    Liou, Jun-Ting
    Cheng, Shih-Hsuan
    Lin, Chen Wei
    Pan, Hsueh-Yi
    Hsu, Yu-Juei
    Tsai, Chen-Liang
    CHEST, 2021, 160 (04) : 1255 - 1270
  • [22] Efficacy and safety of Long-acting Beta-agonists plus Long-acting muscarinic antagonists vs Long-acting Beta-agonists plus Inhaled corticosteroids in COPD: a meta-analysis
    Villalobos, Ralph Elvi
    David-Wang, Aileen
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [23] Risk of Cardiovascular and Cerebrovascular Events in COPD Patients Treated With Long-Acting 2-Agonist Combined With a Long-Acting Muscarinic or Inhaled Corticosteroid
    Samp, Jennifer C.
    Joo, Min J.
    Schumock, Glen T.
    Calip, Gregory S.
    Pickard, A. Simon
    Lee, Todd A.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (11) : 945 - 953
  • [24] Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators
    Skolnik, Neil S.
    Nguyen, Trang Susan
    Shrestha, Aarisha
    Ray, Riju
    Corbridge, Thomas C.
    Brunton, Stephen A.
    POSTGRADUATE MEDICINE, 2020, 132 (02) : 198 - 205
  • [25] Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease
    Petite, Sarah E.
    ANNALS OF PHARMACOTHERAPY, 2017, 51 (08) : 696 - 705
  • [26] Blood eosinophils and inhaled corticosteroid/long-acting β-2 agonist efficacy in COPD
    Pavord, Ian D.
    Lettis, Sally
    Locantore, Nicholas
    Pascoe, Steve
    Jones, Paul W.
    Wedzicha, Jadwiga A.
    Barnes, Neil C.
    THORAX, 2016, 71 (02) : 118 - 125
  • [27] Systematic review and network meta-analysis of the efficacy and safety of glycopyrrolate/formoterol fumarate metered dose inhaler in comparison with other long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combinations in COPD
    Siddiqui, Mohd Kashif
    Shukla, Pragya
    Jenkins, Martin
    Ouwens, Mario
    Guranlioglu, Deniz
    Darken, Patrick
    Biswas, Mousumi
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2019, 13
  • [28] Issues on Safety of Long-Acting Muscarinic Antagonist
    Lee, Yang Deok
    Cho, Yongseon
    Han, Min Soo
    TUBERCULOSIS AND RESPIRATORY DISEASES, 2011, 70 (05) : 384 - 389
  • [29] Cost Effectiveness of Inhaled Corticosteroid/Long-Acting Beta-Agonist/Long-Acting Muscarinic Antagonist (ICS/LABA/LAMA) Coverage Related to Reduction in Risk of Exacerbations
    White, J.
    Szema, A. M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [30] Effects of a single long-acting muscarinic antagonist agent and a long-acting muscarinic antagonist/long-acting β2-adrenoceptor agonist combination on lung function and symptoms in untreated COPD patients in Japan
    Yamada, Hideyasu
    Hida, Norihito
    Hizawa, Nobuyuki
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2018, 13 : 3141 - 3147
12345